Mitochondrial dynamics in pulmonary arterial hypertension

Verfasser / Beitragende:
[John Ryan, Asish Dasgupta, Jessica Huston, Kuang-Huieh Chen, Stephen Archer]
Ort, Verlag, Jahr:
2015
Enthalten in:
Journal of Molecular Medicine, 93/3(2015-03-01), 229-242
Format:
Artikel (online)
ID: 605543364
LEADER caa a22 4500
001 605543364
003 CHVBK
005 20210128100926.0
007 cr unu---uuuuu
008 210128e20150301xx s 000 0 eng
024 7 0 |a 10.1007/s00109-015-1263-5  |2 doi 
035 |a (NATIONALLICENCE)springer-10.1007/s00109-015-1263-5 
245 0 0 |a Mitochondrial dynamics in pulmonary arterial hypertension  |h [Elektronische Daten]  |c [John Ryan, Asish Dasgupta, Jessica Huston, Kuang-Huieh Chen, Stephen Archer] 
520 3 |a Pulmonary arterial hypertension (PAH) is an idiopathic cardiopulmonary disease characterized by obstruction of small pulmonary arteries. Vascular obstruction is the consequence of excessive proliferation and apoptosis resistance of vascular cells, as well as inflammation, thrombosis, and vasoconstriction. Vascular obstruction increases the afterload faced by the right ventricle (RV), leading to RV failure. The proliferative, obstructive vasculopathy of PAH shares several mitochondrial abnormalities with cancer, notably a shift to aerobic glycolysis and mitochondrial fragmentation. Mitochondria in the pulmonary artery smooth muscle cell (PASMC) normally serve as oxygen sensors. In PAH, acquired mitochondrial abnormalities, including epigenetic silencing of superoxide dismutase (SOD2), disrupt oxygen sensing creating a pseudo-hypoxic environment characterized by normoxic activation of hypoxia-inducible factor-1α (HIF-1α). The resulting metabolic shift to aerobic glycolysis (the Warburg phenomenon) reflects inhibition of pyruvate dehydrogenase by pyruvate dehydrogenase kinases. In addition, altered mitochondrial dynamics result in mitochondrial fragmentation. The molecular basis of this structural change includes upregulation and activation of fission mediators, notably dynamin-related protein 1 (DRP-1), and downregulation of fusion mediators, especially mitofusin-2 (MFN2). These pathogenic mitochondrial abnormalities offer new therapeutic targets. Inhibition of mitotic fission or enhancement of fusion in PAH PASMC slows cell proliferation, causes cell cycle arrest, and induces apoptosis. DRP-1 inhibition or MFN2 gene therapy can regress PAH in experimental models of PAH. This review focuses on the etiology of mitochondrial fragmentation in PAH and explores the therapeutic implications of mitochondrial dynamics in the pulmonary vasculature and RV. 
540 |a Springer-Verlag Berlin Heidelberg, 2015 
690 7 |a Apoptosis  |2 nationallicence 
690 7 |a Oxygen sensing  |2 nationallicence 
690 7 |a Dynamin-related protein 1 (DRP-1)  |2 nationallicence 
690 7 |a Mitofusin-2  |2 nationallicence 
690 7 |a Cell proliferation  |2 nationallicence 
700 1 |a Ryan  |D John  |u Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City, UT, USA  |4 aut 
700 1 |a Dasgupta  |D Asish  |u Department of Medicine, Queen's University, Etherington Hall, Room 3041, 94 Stuart St., K7L 3N6, Kingston, ON, Canada  |4 aut 
700 1 |a Huston  |D Jessica  |u Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City, UT, USA  |4 aut 
700 1 |a Chen  |D Kuang-Huieh  |u Department of Medicine, Queen's University, Etherington Hall, Room 3041, 94 Stuart St., K7L 3N6, Kingston, ON, Canada  |4 aut 
700 1 |a Archer  |D Stephen  |u Department of Medicine, Queen's University, Etherington Hall, Room 3041, 94 Stuart St., K7L 3N6, Kingston, ON, Canada  |4 aut 
773 0 |t Journal of Molecular Medicine  |d Springer Berlin Heidelberg  |g 93/3(2015-03-01), 229-242  |x 0946-2716  |q 93:3<229  |1 2015  |2 93  |o 109 
856 4 0 |u https://doi.org/10.1007/s00109-015-1263-5  |q text/html  |z Onlinezugriff via DOI 
898 |a BK010053  |b XK010053  |c XK010000 
900 7 |a Metadata rights reserved  |b Springer special CC-BY-NC licence  |2 nationallicence 
908 |D 1  |a review-article  |2 jats 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-springer 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1007/s00109-015-1263-5  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Ryan  |D John  |u Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City, UT, USA  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Dasgupta  |D Asish  |u Department of Medicine, Queen's University, Etherington Hall, Room 3041, 94 Stuart St., K7L 3N6, Kingston, ON, Canada  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Huston  |D Jessica  |u Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City, UT, USA  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Chen  |D Kuang-Huieh  |u Department of Medicine, Queen's University, Etherington Hall, Room 3041, 94 Stuart St., K7L 3N6, Kingston, ON, Canada  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Archer  |D Stephen  |u Department of Medicine, Queen's University, Etherington Hall, Room 3041, 94 Stuart St., K7L 3N6, Kingston, ON, Canada  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t Journal of Molecular Medicine  |d Springer Berlin Heidelberg  |g 93/3(2015-03-01), 229-242  |x 0946-2716  |q 93:3<229  |1 2015  |2 93  |o 109